Elicio Therapeutics (ELTX) Income from Continuing Operations (2020 - 2026)
Elicio Therapeutics (ELTX) reported Income from Continuing Operations of 10852000.0 for Q1 2026, down 1.4% on a YoY basis from 11006264.59 in Q1 2025, and down 18.23% quarter-over-quarter from 9179000.0 in Q4 2025.
Elicio Therapeutics (ELTX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Elicio Therapeutics has reported Income from Continuing Operations for 7 years, with the latest figure at 10852000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 1.4% year-over-year to 10852000.0; the trailing twelve-month figure through Mar 2026 stood at 38420000.0 (up 15.64% YoY), and the FY2025 full-year result was 38847000.0, up 14.51% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 10852000.0, down from 9179000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 5998000.0 in Q4 2022, with the low at 14485000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 9714411.76 across 5 years, with a median of 10117000.0 in 2025.
- The largest YoY upside for Income from Continuing Operations was 59.99% in 2022 against a maximum downside of 140.99% in 2022.
- Elicio Therapeutics' Income from Continuing Operations stood at 5998000.0 in 2022, then tumbled by 55.37% to 9319000.0 in 2023, then slumped by 47.12% to 13710000.0 in 2024, then jumped by 33.05% to 9179000.0 in 2025, then dropped by 18.23% to 10852000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 10852000.0 (Q1 2026), 9179000.0 (Q4 2025), and 8272000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Elicio Therapeutics | 70.12 Mn | 55.17 Mn | - | -10.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.85 Mn |
| Dec 31, 2025 | -9.18 Mn |
| Sep 30, 2025 | -8.27 Mn |
| Jun 30, 2025 | -10.12 Mn |
| Mar 31, 2025 | -10.70 Mn |
| Dec 31, 2024 | -13.71 Mn |
| Sep 30, 2024 | -10.30 Mn |
| Jun 30, 2024 | -10.84 Mn |
| Mar 31, 2024 | -10.13 Mn |
| Dec 31, 2023 | -9.32 Mn |
| Sep 30, 2023 | -10.53 Mn |
| Jun 30, 2023 | -8.45 Mn |
| Mar 31, 2023 | -8.14 Mn |
| Dec 31, 2022 | -6.00 Mn |
| Sep 30, 2022 | -6.84 Mn |
| Jun 30, 2022 | -7.30 Mn |
| Mar 31, 2022 | -14.49 Mn |
| Dec 31, 2021 | 14.63 Mn |
| Sep 30, 2021 | -15.76 Mn |
| Jun 30, 2021 | -18.24 Mn |